title: Aprindine-induced hepatic granulomata.
abstract: Aprindine is a very effective antiarrhythmic agent with a narrow therapeutic ratio. We report a patient who suffered from granulomatous hepatitis probably due to the administration of aprindine. Evidence of hepatitis appeared within 6 weeks of initiating aprindine therapy and resolved rapidly when the drug was withdrawn. Six months later, fibrosis but no granulomata were found in the expanded portal tracts. Our observations suggest that granulomatous hepatitis can occur during aprindine therapy.
authors.affiliation: Department of Internal Medicine, University of Ioannina, Greece.
authors.forename: M
authors.initials: M
authors.lastname: Elisaf
authors.forename: S
authors.initials: S
authors.lastname: Stefanaki-Nikou
authors.forename: M
authors.initials: M
authors.lastname: Voulgarelis
authors.forename: C
authors.initials: C
authors.lastname: Masalas
authors.forename: E V
authors.initials: EV
authors.lastname: Tsianos
mesh_terms: D001073:Aprindine / Q000009:adverse effects* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury; D005260:Female; D005355:Fibrosis; D006099:Granuloma / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D007249:Inflammation; D008107:Liver Diseases / Q000473:pathology / Q000503:physiopathology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011168:Portal System / Q000473:pathology
chemical_list: D001073:Aprindine